¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"neutrophil lobe count"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • nonfilamented neutrophil
    ¹«¹Ì¼¼¼¶À¯Áß¼º±¸
  • plating colony count technique
    ÆòÆÇ¹è¾çÁý¶ô°è¼ö¹ý
  • segmented neutrophil
    ºÐ¿±ÇÙÁß¼º±¸
  • azygos lobe
    ȬÇãÆÄ¿±, ±â¿±(Ðôç¨)
  • caudate lobe
    ²¿¸®¿±, ¹Ì»ó¿±
  • flocculonodular lobe
    Ÿ·¡°áÀý¿±, Æí¿±¼ÒÀý¿±
  • frontal lobe
    À̸¶¿±, ÀüµÎ¿±
  • frontal lobe epilepsy
    À̸¶¿±°£Áú, ÀüµÎ¿±°£Áú
  • insular lobe
    ´ë³ú¼¶, ³ú¼¶¿±, µµ¿±
  • limbic lobe
    µÑ·¹¿±, º¯¿¬¿±
  • lobe
    ¿±
  • middle lobe syndrome
    Áß°£¿±ÁõÈıº
  • olfactory lobe
    Èİ¢¿±
  • orbital lobe
    ´«È®¿±, ¾È¿Í¿±
  • occipital lobe
    µÚÅë¼ö¿±, Èĵο±
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • parietal lobe
    ¸¶·ç¿±, µÎÁ¤¿±
  • quadrate lobe
    ³×¸ð¿±, ¹æÇü¿±
  • temporal lobe
    °üÀÚ¿±, ÃøµÎ¿±
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • colony count
    Áý¶ô¼ö, Áý¶ô°è»ê
  • complete blood count
    ¿ÂÇ÷±¸°è»ê, ÀüüÇ÷±¸°è»ê
  • differential count
    °¨º°°è»ê
  • differential blood count
    °¨º°Ç÷±¸°è»ê
  • differential leukocyte count
    °¨º°¹éÇ÷±¸°è»ê
  • egg count
    Ãæ¶õ¼ö
  • particle count
    ÀÔÀÚ°èÃø
  • platelet count
    Ç÷¼ÒÆÇ°è»ê
  • radioactivity count
    ¹æ»ç´ÉÃøÁ¤
  • telogen count
    ÈÞÁö±â¸ð¹ß°è¼ö
  • total bacterial count
    Ãѱռö
  • viable count
    »ý±Õ¼ö
  • flocculonodular lobe
    Ÿ·¡°áÀý¿±
  • frontal lobe
    À̸¶¿±, ÀüµÎ¿±
  • insular lobe
    ³ú¼¶¿±
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inferior lobe
    ¾Æ·¡¿±, ÇÏ(ù»)¿±.
  • inferior lobe
    ¾Æ·¡¿±
  • inferior lobe ³ª lobus i.
    ¾Æ·¡¿±, ÇÏ¿± (ù»ç¨).
  • pituitary anterior lobe
    ³úÇϼöü¾Õ¿±, ³úÇϼöüÀü¿±(¡­îñç¨).
  • pituitary intermediate lobe
    ³úÇϼöüÁß°£¿±, ³úÇϼöüÁß¿±(¡­ñéç¨).
  • pituitary posterior lobe
    ½Å°æ ³úÇϼöüµÚ¿±, ³úÇϼöüÈÄ¿±(¡­ý­ç¨).
  • posterior cerebellar lobe
    ¼Ò³úµÚ¿±, ¼Ò³úÈÄ¿±(á³Òàý­ç¨).
  • posterior cerebellar lobe
    ¼Ò³úµÚ¿±
  • posterior lobe
    µÚ¿±, ÈÄ¿±.
  • posterior lobe of hypophysis
    (³ú)Çϼöü ÈÄ¿±.
  • posterior lobe ³ª lobus p.
    µÚ¿±, ÈÄ¿±(ý­ç¨) ÇϼöüÀÇ .
  • prefrontal lobe
    ÀüÀüµÎ¿±.
  • pulmonary lobe
    Æó¿±(øËç¨).
  • pyramidal lobe
    ÇǶó¹Ô¿±, Ãßü(õÞô÷)¿±.
  • pyramidal lobe
    (ÇǶó¹Ô¿±)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • neutrophil leucocyte
    È£Áß¼º ¹éÇ÷±¸(¡­ÛÜúìϹ)
  • neutrophil metamyelocyte
    Áß¼ºÈ£¼º Èİñ¼ö¼¼Æ÷, È£Áß¼º Èİñ¼ö?~ý­ÍéâÐϹ) .
  • neutrophil metamyelocyte
    Áß¼ºÈ£¼º Èİñ¼ö¼¼Æ÷, È£Áß¼º Èİñ¼ö±¸(~Ì·Ë­ËàË´) .
  • neutrophil metamyelocyte
    Áß¼ºÈ£¼º Èİñ¼ö(ñéàõû¿àõý­ÍéâÐ) , ¼¼Æ÷ È£Áß¼º Èİñ¼ö±¸
  • neutrophil myelocyte
    Áß¼ºÈ£¼º °ñ¼ö¼¼Æ÷, È£Áß¼º °ñ¼ö?~ÍéâÐϹ).
  • neutrophil myelocyte
    Áß¼ºÈ£¼º °ñ¼ö¼¼Æ÷
  • neutrophil production
    È£Áß±¸»ý¼º
  • neutrophil specific antigen
    È£Áß±¸Æ¯ÀÌÇ׿ø.
  • neutrophil toxic granule
    È£Áß±¸µ¶¼º°ú¸³
  • nonfilamented neutrophil
    ¹«»çÈ£Áß±¸(ËÎË×̴̡˴).
  • nonfilamented neutrophil
    ¹«»çÈ£Áß?ÙíÞêû¿ñéϹ).
  • polymorphonuclear neutrophil =PMN
    ´ÙÇüÇ٠ȣÁß±¸
  • polymorphonuclear neutrophil[e]
    ´ÙÇÙÈ£Áß±¸
  • segmented neutrophil
    ºÐ¿±ÇÙÈ£Áß±¸
  • analyzer for cell count
    ¼¼Æ÷¼öºÐ¼®±â
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Superior branch of inferior lobe
    ¾Æ·¡¿±À§°¡Áö
    [¿¾ ¿ë¾î] ÇÏ¿±»óÁö
  • Lobe
    ¿±
    [¿¾ ¿ë¾î] ¿±
  • Right hepatic lobe
    ¿À¸¥°£¿±
    [¿¾ ¿ë¾î] ¿ì¿±
  • Right bile duct of caudate lobe
    ¿À¸¥²¿¸®¿±¾µ°³°ü
    [¿¾ ¿ë¾î] ¿ì¹Ì»ó¿±´ã°ü
  • Right lobe
    ¿À¸¥¿±
    [¿¾ ¿ë¾î] ¿ì¿±
  • Left hepatic lobe
    ¿Þ°£¿±
    [¿¾ ¿ë¾î] Á¿±
  • Left bile duct of caudate lobe
    ¿Þ²¿¸®¿±¾µ°³°ü
    [¿¾ ¿ë¾î] Á¹̻󿱴ã°ü
  • Frontal lobe
    À̸¶¿±
    [¿¾ ¿ë¾î] ÀüµÎ¿±
  • Renal lobe
    ÄáÆÏ¿±
    [¿¾ ¿ë¾î] ½ÅÀå¼Ò¿±
  • Flocculonodular lobe
    Ÿ·¡°áÀý¿±
    [¿¾ ¿ë¾î] Æí¼ÒÀý¿±
  • Neurohypophysis [Posterior lobe]
    ½Å°æ³úÇϼöü [µÚ¿±]
    [¿¾ ¿ë¾î] ½Å°æÇϼöü
  • Neurohypophysis [Posterior lobe]
    ½Å°æ³úÇϼöü [µÚ¿±]
    [¿¾ ¿ë¾î] ÈÄ¿±
  • Inferior lobe
    ¾Æ·¡¿±
    [¿¾ ¿ë¾î] ÇÏ¿±
  • Right lung, inferior lobe
    ¿À¸¥ÇãÆÄ, ¾Æ·¡¿±
    [¿¾ ¿ë¾î] ¿ìÆó, ÇÏ¿±
  • Right lung, superior lobe
    ¿À¸¥ÇãÆÄ, À§¿±
    [¿¾ ¿ë¾î] ¿ìÆó, »ó¿±
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • side lobe
    Ãø¿±
  • side lobe artifact
    Ãø¿±Àΰø¹°
  • temporal lobe syndrome
    ÃøµÎ¿±ÁõÈıº
  • upper lobe
    »ó¿±
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
Diff. Differential count; ¹éÇ÷±¸ °¨º° °è»ê
  = diff. count
diff. count differential count; ¹éÇ÷±¸ °¨º° °è»ê
  = Diff.
TEC total electron count; total eosinophil count; total exchange capacity; transient erythroblastopenia ...
WBC well baby care/clinic; white blood cell; white blood cell count; whole blood cell count
ANCA Anti-Neutrophil Cytoplasmic Antibody
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
GFL Giant fiber lobe
MTL Medial Temporal Lobe
MTLE Medial temporal lobe epilepsy
NIL Neurointermediate lobe
TLE Temporal Lobe Epilepsy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • leukocyte differential count
    ¹éÇ÷±¸ ºÐÈ­
  • reticulocyte count
    ¸Á»ó ÀûÇ÷±¸ ¼ö
  • salivary lactobacillus count
    Ÿ¾× À¯»ê±Õ Áö¼ö
  • total count of bacteria
    ÃÑ±Õ ¼ö °èÃø
  • viable count of bacteria
    »ý±Õ¼ö °èÃø
  • white blood cell count
    ¹éÇ÷¼ö
  • white blood count
    ¹éÇ÷¼ö
  • adenohypophysis anterior lobe
    »ù ³úÇϼöü ¾Õ ¿±
  • anterior lobe
    Àü¿±
  • anterior lobe of cerebellum
    ¼Ò³ú¾Õ¿±, Àü¿±
  • corticotropin-like intermediate lobe peptide

    corticotropin-releasing factor (ºÎ½Å ÇÇÁú È£¸£¸ó À¯¸® ¿ä¼Ò, ºÎ½Å ÇÇÁú È£¸£¸ó À¯¸® ÀÎÀÚ

  • developmental lobe
    ¹ßÀ°¿±
    Ä¡¾Æ ¹ßÀ°¿¡¼­ ÀÏÂ÷ÀûÀ¸·Î Çü¼ºµÇ´Â ¿©·¯ ºÎºÐ Áß Çϳª.
  • frontal lobe ataxia
    ÀüµÎ¿± ½ÇÁ¶
  • left bile duct of caudate lobe
    ¿Þ²¿¸®¿± ¾µ°³ °ü
  • left hepatic lobe
    ¿Þ°£¿±
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
absolute eosinophil count <haematology, investigation> A measurement (cells per microlitre) of the number of eosinophils in a blood specimen.
This measurement is useful in the evaluation of autoimmune disease, allergies, eczema, leukaemia, asthma and hay fever. Normal absolute eosinophil counts are less than 350 cells/mcl (microlitre).
(27 Sep 1997)
Addis count A quantitative enumeration of the red blood count, white blood count, and casts in a 12-hr urine specimen; used to follow the progress of known renal disease.
(05 Mar 2000)
Arneth count The percentage distribution of polymorphonuclear neutrophils, based on the number of lobes in the nuclei (from 1 to 5).
See: Arneth index.
(05 Mar 2000)
b and t cell count A test that measures the respective quantities of B lymphocytes and T lymphocytes. This test is often performed in the analysis of an immune deficiency disorder. Normal values include: 68 to 75% of total lymphocytes are T lymphocytes and 10 to 20% are B lymphocytes.
Increased T-cell counts can indicate infectious mononucleosis, acute lymphocytic leukaemia or multiple myeloma.
Increased B lymphocytes can indicate chronic lymphocytic leukaemia, multiple myeloma, Waldenstrom's macroglobulinaemia or Di George syndrome. Decreased T-cells may indicate congenital T-cell deficiency, Wiskott-Aldrich syndrome or AIDS. Decreased B-cells may indicate acute lymphocytic leukaemia or a congenital immunoglobulin deficiency disorder.
(27 Sep 1997)
blood cell count A count of the number of leukocytes and erythrocytes per unit volume in a sample of venous blood. A complete blood count (cbc) also includes measurement of the haemoglobin, haematocrit, and erythrocyte indices.
(12 Dec 1998)
blood count <haematology, investigation> The determination of the proper number of red blood cells, white blood cells and platelets are present in the patients blood.
Acronym: FBC
(16 Dec 1997)
red blood cell count A normal value is 4.6-6.2 million RBC's per cubic millimetre of blood. This number can increase in cases of dehydration (fluid loss) or severe lung disease. Interestingly, red blood cell counts are much higher in those who live at high altitude, because of the increased demand for oxygen carrying capacity.
(27 Sep 1997)
viable cell count Number of cells in a given area or volume that are thriving.
(05 Mar 2000)
viable count Measurement of the concentration of live cells in a microbial population.
(09 Oct 1997)
CD4/CD8 count The ratio of the number of helper-inducer T lymphocytes to cytotoxic-suppressor T lymphocytes, as measured by monoclonal antibodies to the CD4 surface antigen found on helper-inducer T-cells, and the CD8 surface antigen found on cytotoxic-suppressor T-cells. In healthy individuals, the H/S ratio ranges between 1.6 and 2.2.When the body mounts an immune response, as against a virus or a transplant, the ratio is almost always reduced because of a decrease in the number of circulating helper-inducer cells and an increase in suppressor cells. The CD4/CD8 count has been used to monitor for signs of organ rejection after transplants, and more recently has become a tool for assessing the relative condition of HIV patients. With the CD4 absolute count and the CD4 lymphocyte percentage, it provides a way of gauging the progression from HIV to AIDS.
(05 Mar 2000)
CD4 cell count The most commonly used surrogate marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. The normal range for CD4 cell counts is 500 to 1500 per cubic millimetre of blood. CD4 count should be rechecked at least every six to twelve months if CD4s are greater than 500/mm3. If the count is lower, testing every three months is advised.
(09 Oct 1997)
CD4 count, absolute The number of helper T-lymphocytes in a cubic millimeter of blood. With HIV, the absolute CD4 count declines as the infection progresses. The absolute CD4 count is frequently used to monitor the extent of immune suppression in persons with HIV. Also called a T4 count.
(12 Dec 1998)
CD4 lymphocyte count A count of the number of CD4-positive lymphocytes in the blood. Determination requires the use of a fluorescence-activated flow cytometer.
(12 Dec 1998)
cell count A count of the number of cells of a specific kind, usually measured per unit volume of sample.
(12 Dec 1998)
reticulocyte count Determination of the number of reticulocytes in a measured volume of blood. Values for reticulocytes are expressed as a percentage of the erythrocyte count or in the form of a so-called "corrected" reticulocyte "index". An increase in circulating reticulocytes, often referred to as reticulocytosis, is among the simplest and most reliable signs of accelerated erythrocyte production. Reticulocytosis, or an increased reticulocyte count, occurs during active blood regeneration (stimulation of red bone marrow) and in certain anaemias, particularly congenital haemolytic anaemia.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • count-out
    Á¤Á·¼ö(40¸í)¹Ì´Þ·Î ÀÎÇÑ À¯È¸;Á¦¿ÜÇ¥(¿¡ ÀÇÇÑ ³«¼±ÀÚ);Ä«¿îÆ®¾Æ¿ô a
  • head count
    ¿©·Ð(±¹¼¼)Á¶»ç
  • nose count
    Àοø¼ö ¼¼±â;´Ù¼ö°á
  • pollen count
    ²É°¡·çÀÇ ¼ö !
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á